Recent News

July 28, 2010 - Pfenex Announces Sponsorship of the 13th MipTec - The Leading European Event for Drug Discovery on September 21-24, 2010, Basel, Switzerland

June 29, 2010 – Intercell AG presents the details of their Pfenex Expression Technology based production process for their Phase 3 Traveler’s Diarrhea Prophylactic Vaccine Candidate

June 14, 2010 – SAIC Presents a Pfçnex Expression Technology Case Study at the Vaccine Production Summit in San Diego

May 18, 2010 – Sanofi Pasteur Presents a Pfçnex Expression Technology Case Study at the Sixth Annual PEGS Conference in Boston

May 17, 2010 - Xcellerex, Pfenex Inc and Collaborators Complete Successful Test

April 6, 2010 - Boston BioCom LLC Announces Continued Advancement of Jantibody Therapeutics LLC Subsidiary

March 29, 2010 - Ranbaxy and Pfçnex Announce Collaboration for the Development of a Biosimilar Therapeutic Protein

December 14, 2009 - Pfçnex Inc. completes license deal with Merck & Co., Inc. - $52MM in upfront and milestone payments plus royalties

December 8, 2009 - Pfçnex Inc. completes spin out from the Dow Chemical Company

Product Announcements

July 2010 – Pfenex launches reagent grade Granulocyte colony – stimulating factor (GCSF) and Interferon beta 1B

October 2009 - Pfenex is now offering bulk reagent grade and cGMP recombinant CRM197 a non-toxic variant of diphtheria toxin used as a protein carrier in vaccine applications.

For more information on Pfenex products please visit our reagents proteins page.